News & Perspective

Jul 18, 2006

Jul 18, 2006

Novartis to build US cell-based flu vaccine plant

(CIDRAP News) – Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.

The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.